Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial

• Published in: The lancet. Diabetes & endocrinology Vol. 1; no. 4; pp. 306 - 316
• Main Authors: Gitelman, Stephen E, Gottlieb, Peter A, Rigby, Mark R, Felner, Eric I, Willi, Steven M, Fisher, Lynda K, Moran, Antoinette, Gottschalk, Michael, Moore, Wayne V, Pinckney, Ashley, Keyes-Elstein, Lynette, Aggarwal, Sudeepta, Phippard, Deborah, Sayre, Peter H, Ding, Linna, Bluestone, Jeffrey A, Ehlers, Mario R
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.12.2013
• Subjects: Adolescent; Adult; Antilymphocyte Serum - therapeutic use; Child; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - diagnosis; Diabetes Mellitus, Type 1 - drug therapy; Double-Blind Method; Endocrinology & Metabolism; Female; Humans; Immunologic Factors - therapeutic use; Male; Other; Time Factors; Treatment Outcome; Young Adult

Type 1 diabetes results from T-cell-mediated destruction of β cells. Findings from preclinical studies and pilot clinical trials suggest that antithymocyte globulin (ATG) might be effective for reducing this autoimmune response. We assessed the safety and efficacy of rabbit ATG in preserving islet f...